MedTrace Logo

Reference Measurements of the Neuronal Integration Window and Anatomical and Functional MRI (Magnetic Resonance Imaging)

NCT07453108 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-05

No results posted yet for this study

Summary

Our studies on MRI (Magnetic resonance imaging) biomarkers in neuropsychiatric disorders rely on reference data from control subjects which are dependent from our scanner. Due to the upcoming replacement of our MR scanner, the investigators need to 'recalibrate' our current database by acquiring the same data on both the old and the new device from a small group of controls (n = 36 to 40). This will be combined with measures of cortical excitability using robotized TMS (transcranial magnetic stimulation) that will be combined to MRI biomarkers in forthcoming studies.

Therefore, the primary objective of this biomedical trial is to collect MRI and physiological measurements in normal subjects whose characteristics match to our study populations.

Conditions

  • Neuropsychiatric Disorders

Interventions

OTHER

MRI (Magnetic Resonance Imaging)

2 MRI sessions on 3 Tesla Vério Siemens scanner at V1, separated by minimum one week Anatomical and functional measures: * 3 ASL-fMRI with ET = 9.7 ms, 3 ASL-fMRI with ET = 21 ms during various tasks. * Multiparametric quantitative measures (NODDI, R1, R2, R2\*, magnetic susceptibility, macromolecular proton fraction). * 3DT1 and 3D FLAIR.

OTHER

TMS (Transcranial Magnetic Stimulation)

1 session at visit V2. Intracortical inhibition, neuronal integration and window of simultaneity Mapping of passive and active motor evoked potential MEP using dedicated robotic device under the control of neuronavigation. + cortical and trans-cortical silence period

OTHER

MRI (Magnetic Resonance Imaging)

2 MRI sessions on 3 Tesla Vida scanner at V3, separated by minimum one week. 2 MRI sessions on "new" MR-scanner Anatomical and functional measures: * 3 ASL-fMRI with ET = 9.7 ms, 3 ASL-fMRI with ET = 21 ms during various tasks. * Multiparametric quantitative measures (NODDI, R1, R2, R2\*, magnetic susceptibility, macromolecular proton fraction). * 3DT1 and 3D FLAIR.

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Jack FOUCHER · CEntre de neuroModulation Non-Invasive de Strasbourg (CEMNIS)

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-17
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07453108 on ClinicalTrials.gov